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Abstract
Background: The survival of glioma patients with the current treatments is poor. Early clinical trails with replicating
adenoviruses demonstrated the feasibility and safety of the use of adenoviruses as oncolytic agents. Antitumor
efficacy has been moderate due to inefficient virus replication and spread. Previous studies have shown that
truncation of the adenovirus i-leader open reading frame enhanced cytopathic activity of HAdV-5 in several tumor
cell lines. Here we report the effect of an i-leader mutation on the cytopathic activity in glioma cell lines and in
primary high-grade glioma cell cultures.
Results: A mutation truncating the i-leader open reading frame was created in a molecular clone of replication-
competent wild-type HAdV-5 by site-directed mutagenesis. We analyzed the cytopathic activity of this RL-07
mutant virus. A cell-viability assay showed increased cytopathic activity of the RL-07 mutant virus on U251 and
SNB19 glioma cell lines. The plaque sizes of RL-07 on U251 monolayers were seven times larger than those of
isogenic control viruses. Similarly, the cytopathic activity of the RL-07 viruses was strongly increased in six primary
high-grade glioma cell cultures. In glioma cell lines the RL-07 virus was found to be released earlier into the
culture medium. This was not due to enhanced viral protein synthesis, as was evident from equivalent E1A, Fiber
and Adenovirus Death Protein amounts, nor to higher virus yields.
Conclusion: The cytopathic activity of replicating adenovirus in glioblastoma cells is increased by truncating the i-
leader open reading frame. Such mutations may help enhancing the antitumor cytopathic efficacy of oncolytic
adenoviruses in the treatment of glioblastoma.
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Background
The poor prognosis of high grade gliomas with the cur-
rent treatments prompted an ongoing search for alterna-
tive treatments. A new strategy for glioma treatment
involves the use of viruses as oncolytic agents, such as
Human Adenoviruses (HAdV), Herpes Simplex viruses
and, more recently Reoviruses [1-5]. Of these, the use of
HAdV has been explored most rigorously, including
replication-defective HAdV vectors carrying heterologous
transgenes, as well as replication-competent HAdV in
which replication is restricted to tumor cells.
HAdV transduce both dividing and quiescent cells
with high efficiency, they can be genetically modified
with relative ease, and the technology for clinical-grade
production is available. Their biology, which is under-
stood in detail, also facilitates modification of the viral
genome for creating Conditionally-Replicating Adeno-
viruses (CRAds). In addition, viral-tissue tropism can be
modified by incorporating ligands that target specific
receptors on tumor cells, for example by fusing ligands
with the fiber [6] or with the minor capsid protein IX
[7]. Also modifications have been described that pro-
mote interactions with the tumor-specific receptors.
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target tissues [8-11].
The first phase I clinical trial with a replication-com-
petent HAdV on malignant glioma was performed with
ONYX-015 [1], which is based on HAdV-5 and harbors
a deletion in the open reading frame encoding the 55
kDa E1B protein [12]. Although ONYX-015 has anti-
tumor activity, the precise mechanism behind its tumor-
cell preference is still controversial [13]. While the
ONYX-015 study provided evidence of the safety of
CRAds in glioma-patients [1], the anti-tumor efficacy of
this virus was limited, presumably due to inefficient
replication and poor intratumoral spread.
To isolate HAdV-5 mutants with improved cytopathic
activity, two groups used random mutagenesis and bio-
selection strategies. Both studies yielded mutants con-
taining point mutations in the i-leader region of the late
transcription unit [14,15]. The i-leader is a 440-nucleo-
tide long sequence that is found between the 2
nd and
3
rd element of the tripartite-leader sequence in a signifi-
cant fraction of the major-late transcripts. This sequence
contains an open reading frame which encodes a small
protein of approximately 16 kDa in size [16]. It has
been suggested that it reduces the half-life of L1
mRNAs, however the precise function of the i-leader
protein is unknown [16,17]. A common point mutation,
C8350T, which created a stop codon in the i-leader
open reading frame, was isolated by Yan et al [15] after
bioselection on the HT29 colon carcinoma cell line.
Also the C8299T mutation, isolated by Subramanian
and coworkers in a screen for large plaques on A549
adenocarcinomic human alveolar basal epithelial cells,
truncated the i-leader open reading frame [14]. Yan and
colleagues demonstrated that their mutants ONYX-201
and ONYX-203, which contain next to the i-leader
mutation some additional mutations, strongly enhanced
the cytopathic activity of HAdV-5 not only in the cells
used for bioselection, but in a larger panel of tumor cell
lines [15]. Unfortunately, no glioma cell lines were
included in their study.
In this study we compared the cytopathic activity of a
HAdV-5 virus containing the single i-leader point muta-
tion with that of wtHAdV-5 in glioma cultures. To do so,
we created a HAdV-5 that contains the C8350T muta-
tion, which truncates this open reading frame. To facili-
tate identification of the mutant-virus genomes, an XhoI
restriction site was created 6 nucleotides downstream of
this mutation. We found the cytopathic activity in glioma
cells of the mutant vector (RL-07) to be strongly
increased compared to the wild-type vector (wtHAdV-5).
While the mutation does not affect timing of viral protein
synthesis and virus yields, the mutant virus was found to
be released earlier from infected cells. These results
demonstrate that improved adenoviruses with enhanced
spreading activity in glioma cells can be generated by
introduction of a mutation that truncates the i-leader.
Such mutations may help enhancing the antitumor effi-
cacy of oncolytic adenoviruses in the treatment of
gliomas.
Materials and methods
Cell lines
In this study we used the malignant glioma cell lines
U251 and SNB19, the HAdV-5 E1 transformed human
embryonic retinoblast cell lines 911 and PER.C6, and
the A549 lung carcinoma cell line as described before
[18]. Cultures of freshly resected glioma cells were
started from resection material of the Dept of Neurosur-
gery at Erasmus MC and used before the fifth passage.
All cell lines were cultured in Dulbecco’sm o d i f i e d
Eagle’s medium (DMEM, Gibco-BRL, Breda, the Nether-
lands) supplemented with 8% fetal bovine serum (FBS,
Gibco-BRL) and penicillin-streptomycin at 37°C in a
humidified atmosphere containing 5% CO2.
Adenovirus vector
We used replication-competent HAdV-5 vectors. The
mutant, containing the i-leader mutation C8350T and
the extra XhoI restriction site (HAdV-5/RL-07), was
generated by homologues recombination in E. coli
BJ5183, using the pTG3602 plasmid [19] as backbone.
The mutated i-leader fragment was generated by muta-
genesis PCR using synthetic oligo nucleotides 5’-
GACAACATCGCGTAGATGACTCGAGTCCATGG
TCTGG and 3’- CCAGACCATGGACTCGAGTCATC
TACGCGATGTTGTC. The nucleotide corresponding
to nt 8350 is represented in bold, and the XhoI restric-
tion site is italicized and underlined. The HAdV-5/RL-
07 virus was rescued on 911 cells, propagated on PER.
C6 cells, purified by double CsCl density gradient centri-
fugation, dialyzed, and stored at -80°C in sucrose buffer.
Infectious particle titers were determined by plaque
assay on 911 cells. The presence of the C8350T muta-
tion and the XhoI restriction site was verified by
sequence analyses (supplementary data). The wtHAdV-
5 virus used in this study was recovered in identical
manner, using a wt HAdV-5 i-leader fragment, to
ensure isogenicity of the RL-07 virus and the wtHAdV-
5. The nucleotide sequence of the entire RL-07 virus is
available upon request.
Viral titer
Plaque assays were performed to determine the biologi-
cal titers (as plaque forming units per ml) as described
[20]. Briefly, 911 cells were seeded in 6-well plates 1 day
prior to viral infection. The cultures were exposed to
serial dilutions of the virus. After 4 hours viral medium
was removed and cells were overlaid with 0.5% agar/F15
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were read at day 10 post infection (p.i.).
The concentrations of viral genome copies were deter-
mined by picogreen assay [21]. Purified virus was inacti-
vated in a final concentration of 0.05% SDS in storage
buffer and loaded in microtiter plates. After adding
picogreen, the fluorescence was measured and viral gen-
omes were calculated using purified bacteriophage l
DNA as a standard.
Propagation on 911 cells
911 cells were seeded in 6-well plates 1 day before infec-
tion. Cultures were infected with wtHAdV-5 or RL-07 in
parallel MOI = 3. 48 hrs p.i. virus was harvested and
viral titers were defined by plaque assays as described
above.
Cell viability assay
WST-1 reagent (Roche, Woerden, The Netherlands) was
used to determine the viability of the cultures after ade-
noviral infection. Cells were seeded in 96-well plates
and infected with various amounts of virus. The cell via-
bility of the cultures was determined 4 days p.i. for the
established cell lines, and 7 days p.i. for the primary
glioma cultures by adding the WST-1 reagent according
to the manufacturer’s instructions.
Viral plaque formation
The plaque surfaces were determined on U251 cells
according the plaque titration protocol as for 911 cells.
The agar was removed 10 days p.i., and the cells were
subsequently fixed with methanol and stained with 0.5%
crystal violet solution. The relative plaque surfaces were
determined with Olympus DP-software.
Viral release
To determine the viral release, media and cells were col-
lected separately at 30 and 48 hrs p.i. of U251 and
SNB19 cultures infected with wtHAdV-5 and RL-07 at
MOI = 3. The titers were determined by plaque titration
on 911 cells.
Immunoblot procedure
To study the viral protein synthesis after infection an
immunoblot procedure was used. U251 and SNB19
were seeded in 6-well plate o/n and infected with RL-07
or HAdV-5 at MOI = 1. Cells were harvested 24, 40, 48,
64, and 70 hrs p.i. in radioimmunoprecipitation assay
lysis buffer (Ripa) (50 mM Tris-Cl, pH 7.5, 150 mM
NaCl, 0.1% SDS, 0.5% DOC, and 1% NP40) supplemen-
ted with protease inhibitors (Complete mini tablets,
Roche Diagnostics, Almere, The Netherlands). Per sam-
ple 50 μg of protein lysate, defined by the Pierce BCA
protein assay kit (Thermo Scientific Rockford, USA),
and after addition of western sample buffer (final con-
centrations: 10% glycerol, 2% SDS, 50 mM Tris-Cl (pH
6.8), 2.5% b-mercaptoethanol and 0.025% bromophenol
blue) was loaded onto a SDS-polyacrylamide gel. The
proteins were transferred to Immobilon-P (Millipore,
Etten-Leur, The Netherlands). Detection of fiber, E1A
and ADP was performed with the antibodies 4D2 (anti-
fiber tail [22]) and M73 (anti-E1A [23]), a rabbit anti-
serum raised against an ADP peptide (P63-77 [24]; a
kind gift from Dr. W. S. M. Wold), respectively, and
visualized by enhanced chemiluminescence. ImmunO
anti-actin clone C4 (MP Biomedicals, Amsterdam, The
Netherlands) was used as loading control.
Colony-based survival assay
Suspensions of U251 and SNB19 were infected with
wtHAdV-5 or RL-07 with a MOI = 100 in 2%FBS/
DMEM, non-infected cells were used as control. Cells
were incubated for 1 hr at 37°C, washed 3 times with
PBS supplemented with 1:500 diluted Immunoglobluline
I.V. (stock 60 mg/ml) and plated in a concentration of
500 cells/dish, medium wass u p p l e m e n t e dw i t h1 : 5 0 0
dilution of IVIG. After 10 days cells were fixed with
methanol and stained with 0.5% crystal violet solution.
Single colonies were counted and number of colonies of
wtHAdV-5 was compared to the number RL-07
colonies.
Trypan blue exclusion-based survival assay
This procedure was performed as described by Tollefson
et al [25]. In short, U251 and SNB19 were seeded at
4.10
5 cells per well in a 6-well plate. The next morning
cells were infected with MOI = 100 in 1 ml DMEM/2%
FBS. After 2 hr 1 ml DMEM/14%FBS was added to each
well. From day 1 up to day 5 media and cells were har-
vested and trypan blue was added to the cells in a final
concentration of 0.02%. A total of 500-600 cells were
counted and percentage of viable cells was calculated.
Results
The aim of this study was to evaluate whether trunca-
tion of the i-leader open reading frame enhances the
cytopathic effect of HAdV-5 in human glioma cell lines.
Since the ONYX-234 virus [15], which consists of
HAdV-5 with the C8350T mutation, was unavailable to
us, we recreated this mutant by site-directed mutagen-
esis and homologous recombination. To facilitate
straightforward identification of this mutant, we inserted
an XhoI-restriction site 6 nucleotides downstream of the
C8350T mutation (additional files 1 and 2). From the
cloned virus DNA, viruses were generated by transfec-
tion of the viral genomes on 911 helper cells. Viral pla-
ques were picked and the viruses expanded and
propagated on PER.C6 cells. No consistent differences
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observed (table 1) in RL-07 and wtHAdV-5 virus bathes
produced in parallel. Also on 911 cells, the RL-07
viruses could be propagated efficiently, with the kinetics
and yields very similar to the wtHAdV-5 (table 2).
To analyze the cytopathic activity of RL-07, two glioma
cell lines (U251 and SNB19, both CAR-positive) and
two control cell lines (911 and A549) were infected with
RL-07 and wtHAdV-5 at multiplicity of infections
(MOI) ranging from 0 to 100 pfu/cell. Four days p.i., the
cell viability was determined by WST-1 assay (Figure 1),
RL-07 had a significant higher cytopathic effect on
glioma cell lines and A549 compared to the control
virus wtHAdV-5. On 911 cells, no differences in the
induction of cytopathic effects were detected.
To determine whether the decreased viability of RL-07
infected cells in the WST-1 assay correlates with
enhanced spread in monolayers of glioma cells, a plaque
assay was performed on U251 cells. Monolayers of U251
were infected with RL-07 and wtHAdV-5 with a 10
9
times diluted virus stock (batch 1) and overlaid with
agar. Plaque sizes were scored 10 days p.i. (Figure 2).
The plaques formed upon infection with RL-07 are on
average 7-fold larger in size than the plaques obtained
with wtHAdV-5, demonstrating that the mutation
enhances viral spread.
To compare the kinetics of virus release, U251 and
SNB19 cells were infected with either RL-07 or
wtHAdV-5. At 30 and 48 hours p.i. the medium was
carefully separated from the adherent cells and both
were collected. In both fractions the viral particles were
quantified by plaque assays on 911 cells (Figure 3). In
both cell lines approximately 7-fold more virus was
found in the medium of the RL-07 infected cells than in
the medium of the wtHAdV-5 infected cells at 30 hrs p.
i.. At 48 hrs p.i. media of RL-07 infected U251 cells con-
tained approximately 22 times more virus than those
infected with wtHAdV-5. Similarly, the amount of RL-
07 in the media of SNB19 cultures was at least 13 times
higher at 48 hrs p.i.. From these data we conclude that
the RL-07 virus is released in to the medium earlier
than wtHAdV-5.
Having established that the RL-07 virus was released
earlier than wtHAdV-5, we examined the expression
pattern of the viral proteins E1A, fiber, and the adeno-
virus death protein (ADP). U251 and SNB19 cells were
infected at MOI = 1 and harvested at several time points
after infection and viral proteins were visualized by
immunoblotting (Figure 4). In our time series no differ-
ences between fiber, E1A and ADP levels were observed
between RL-07 and wtHAdV-5. This shows that the
rapid release of RL-07 particles does not result from
more rapid viral protein synthesis.
In addition to the WST-1 assay, which determines the
metabolic activity of the remaining viable cell popula-
tion, two more direct survival assays were performed.
These are the colony-based survival assay and the trypan
blue exclusion-based survival assay. The colony-based
survival assay measures the number of residual colony-
forming cells after exposure of the cells to the virus. In
this assay no differences in the number of colonies were
noted between wtHAdV-5 and RL-07-infected U251 or
SNB19 cells (data not shown). With the trypan-blue
based assay the fraction of dead cell was assessed by try-
pan-blue, starting 1 day after infection with MOI = 100.
Up to day 5 the cell viability of the U251 and SNB19
cultures were determined and plotted (Figure 5). At one
day p.i. there was no increase in cell death discernable.
At two days after infection the viability started to
decrease. On the U251 cells no differences were
observed between the two viruses. On the SNB19 cell
line, from day 2 up to day 5 p.i. a significant higher pro-
portion of dead cells were detected in the cultures
infected with RL-07 compared to wtHAdV-5. This indi-
cated that RL-07 accelerates cell death on this cell line.
So far our results demonstrate that the i-leader muta-
tion in RL-07 accelerates virus release and enhances
spread in established glioma cell lines. However, the
potency of oncolytic HAdV can differ remarkably
between established cell lines and cultures derived from
resection material. To verify the cytopathic activity of
RL-07 in human gliomas, cultures established from
resection material of high grade gliomas were used for
cytolysis assays. The characteristics of the cultures used
in this study are summarized in Table 3. The cytopathic
activities of the viruses were evaluated 7 days p.i. by
WST-1 assay. The results are presented in Figure 6. At
MOI = 10 and MOI = 100 all RL-07-infected cultures
showed a significantly increased cytopathic activity in
Table 1 Overview viral yield in pfu/ml and vp/ml after
CsCl-purification
Plaque assay Picogreen assay vp/pfu ratio
Batch 1 wtHAdV-5 3×1 0
11 pfu/ml 5.5 × 10
12 vp/ml 18
RL-07 1.1 × 10
11 pfu/ml 1.6 × 10
12 vp/ml 15
Batch 2 wtHAdV-5 2.8 × 10
11 pfu/ml 3.2 × 10
12 vp/ml 11
RL-07 1.3 × 10
11 pfu/ml 1.6 × 10
12 vp/ml 12
Table 2 Viral yield (pfu) of wtHAdV-5 and RL-07 on 911
cultures
wtHAdV-5 RL-07
culture 1 1.35E+09 1.24E+09
culture 2 1.42E+09 1.13E+09
culture 3 1.25E+09 1.34E+09
Average 1.34E+09 1.23E+09
SD 8.81E+07 1.08E+08
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EMC-1, EMC-9 and EMC-24, a significant effect could
already observed at MOI = 1.
Discussion
In our long term efforts of developing efficacious adeno-
viruses for gene therapy in glioma [9,18,26-30], we stu-
died the effect of a truncating mutation in the i-leader
open reading frame on adenovirus cytopathic activity in
glioma cell lines and cell cultures. Our data show that
this mutation results in more rapid release of progeny
viruses into the culture medium and enhanced spread of
the virus in plaque assays. While the precise mechanism
for this effect remains to be elucidated, the improved
cytopathic activity may be employed in new oncolytic
adenoviruses. Our data confirm and extend the results
described by Yan et al [15]. These authors isolated the
ONYX-201 and ONYX-203 viruses by bioselection on
HT29 cells. These viruses harbor several mutations, and
share four mutations including the i-leader truncating
C8350T mutation. Subsequently these authors generated
the ONYX-234 virus that only harbors the C8350T
mutation, and show that this mutation enhances the
adenovirus’s capacity to kill HT29 cells. We confirm
Figure 1 Relative survival as determined by WST-1 assay. Cytopathic activity of RL-07 (grey bar) compared to wtHAdV-5 (black bar) is higher
on glioma cell lines U251 and SNB19. Error bars represent the SD (n = 3). * - statistical significance; unpaired, two-sided t-test, p < 0.01. Cells were
seeded in 96-well plates 1 day before infection with RL-07 and wtHAd5 (MOI range 0-100 pfu/cell). Viability of the cultures was determined 4
days p.i by WST-1 assay. Very similar results were obtained in a repeat experiment.
Figure 2 Viral plaque formation on U251 cells. Monolayers of U251 were infected with RL-07 or wtHAdV-5 with a MOI of 2.2 × 10
-5 and 6 ×
10
-5 respectively, and overlaid with 0.5% agar in F15 media supplemented with 2% Horse serum. Ten days p.i. the agar was removed and cells
were stained with 0.5% crystal violet solution. (A) Photograph of plaques of wtHAdV-5 and RL-07 on U251 monolayer (B) Relative plaque surface
of 10 plaques. *-statistical significance; unpaired, two-sided, t-test, p < 0.01. wtHAdV-5 - black closed triangles; RL-07 - grey closed triangles.
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truncation of the open reading frame enhances the ade-
novirus’s cytopatogenicity in glioma cells.
Similar to Subramanian et al [14], we found that the i-
leader mutation did not affect virus yield and produc-
tion kinetics. In addition, no consistent differences in
particle to pfu ratios were observed in batches produced
in parallel. In a side by side comparison we demon-
strated that RL-07 is more cytopathic on A549 and the
glioma cell lines U251 and SNB19 than the isogenic
wtHAdV-5. The increased cytopathic activity observed
on these cell lines is similar to the observations of Yan
et al with Onyx-234 on HT29 [15].
Enhanced spread was observed on U251 (Figure 2)
with a 7-fold increase in plaque surface. This is in line
with published data of the other i-leader mutants
[14,15]. There is a broad variation in plaque surfaces for
both viruses. As discussed by Subramanian et al this
may be attributable to stochastic fluctuations in virus
infection and replication [14]. The enhanced spread on
U251 can be explained by the more rapid release of RL-
07 from the cells. This is not caused by enhanced DNA
replication (data not shown) confirming observations of
Soloway and Shenk [17] and Subramanian [14], nor by a
changed kinetics of protein synthesis of fiber, E1A and
ADP (Figure 3). These results are similar to the results
of Subramanian and co-workers, who also demonstrated
that the improved viral spread is independent of ADP
expression [14]. In contrast to the data of Yan et al [15],
we found no evidence that the truncating i-leader
Figure 3 Virus releases in culture media.A t3 0a n d4 8h r sp . i .w i t hw t H A d V - 5a n dR L - 0 7t h ec e l l sa n dt h em e d i ao ft h eU 2 5 1a n dS N B 1 9
cultures were collected separately and assayed in a plaque assay. The fraction of the total yield recovered in the medium is plotted. Black bars
represent wtHAdV-5 and the grey bars RL-07. Error bars represent the SD (n = 3)* - statistical significance; unpaired, two sided t-test.
Figure 4 Protein immunoblot assay for detection of viral proteins. Fiber, E1A, ADP levels were detected upon infection with RL-07 or
wtHAdV-5 at various time points p.i.. Actin was used as loading control. Cells were seeded o/n in a 6-well plate and infected with MOI = 1. Cells
were harvested 24, 40, 48, 64 and 70 hrs p.i. in Ripa buffer. Protein amounts were determined by BCA protein assay. In each lane 50 μgo f
protein was loaded. C-mock infected control; W- infected with wtHAdV-5; R- infected with RL-07.
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or viral yields. The reason for this discrepancy is unclear
but may relate to differences in the cell system used
(glioma cells vs. colorectal carcinoma cells). It is also
conceivable that any of the other six mutations in the
ONYX-201 and ONYX -203 viruses have contributed to
the differences between the results of the Yan study and
ours [15].
Our data provide clear evidence for enhanced cyto-
pathicy of the RL-07 virus in glioma cell cultures. To
test whether this is caused by more rapid cell death
upon infection or to enhanced virus spread we used
several assays to assess cell viability. The WST-1 assay
measures the metabolic activity of the residual viable
cells in a culture, and is unable to distinguish these
two components. The involvement of ADP in early cell
death is unlikely since there is no difference between
ADP expression in RL-07 and HAdV-5 infected cells.
A more direct viability assays is the colony-formation
survival assay which yielded very similar results with
RL-07 and wtHAdV-5. Also a more direct assessment
of cell killing on a per-cell basis is the assay by trypan-
blue exclusion. This assay revealed that there was no
difference in cell death between the two viruses in
U251 cells. On SNB19 cells a slightly more rapid cell
death was observed in cultures infected with RL-07
compared to wtHAdV-5. The reason for the difference
between the U251 cells and the SNB19 cells is unclear.
Nevertheless, our data imply that although metabolic
viability of U251 cultures infected with RL-07
decreases faster than in wtHAdV-5 infected cultures,
this is not reflected in a more rapid cell killing by RL-
07. In both cell types there is a strong increase in the
release of infectious viral particles early after infection
(Figure 3).
In the last set of experiments the cytopathic activity of
RL-07 was determined on primary glioma cell cultures.
Primary cell cultures resemble the original tumor more
than established tumor cell lines. Also in these cultures,
we observed significant increased cytotoxic activity of
RL-07 in all the cell lines tested. These results confirm
that RL-07 exhibits an increased cytopathic activity in
low passage cultures of resected glioma cells.
To enhance the potency and reduce the toxicity of
adenovirus vectors the replication of HAdV-5 vectors
for glioma therapy has been restricted by using promo-
ters that are preferentially expressed in tumor cells for
driving expression of key viral genes such as E1A. Also
the tropism of the viruses has been modified by fiber
modifications to increase the transduction of tumor
cells and/or to decrease the transduction in non-target
cells. New mutations such at the mutation that trun-
cates the i-leader open reading frame may prove very
useful for optimizing such vectors by increasing their
the spread. With the fiber-swap mutations [9] and the
optimized glial fibrillary acidic protein promoter [18,28],
the mutation truncating the i-leader open reading frame
protein constitutes a new addition to our arsenal of vali-
dated modules for inclusion in new replicating glioma-
targeted adenoviruses.
Conclusion
In conclusion, truncating the i-leader of HAdV-5 by a
single point mutation will give increased cytopathic
activity in glioma cells. Introducing this mutation in an
oncolytic adenovirus may enhance the antitumor cyto-
pathic efficacy in the treatment of glioblastoma.
Figure 5 Trypan blue-based survival assay. U251 and SNB19 cultures were infected with wtHAdV-5 or RL-07 with a MOI of 100. Cell death in
the cultures was determined by trypan blue as described by Tollefson and colleagues [25]. Error bars represent the SD (n = 3) * - statistical
significance; unpaired, two sided t-test, p < 0.01. ♦ - wtHAdV-5 infected and ▲ - RL-07 infected.
Table 3 Characteristics primary glioma cell cultures
Tumor specimen Male/Female Age Histology
EMC-1 M 44 Anaplas. Astrocytoma
EMC-3 M 48 Glioblastoma multiform
EMC-9 M 66 Glioblastoma multiform
EMC-24 M 50 Glioblastoma multiform
EMC-26 F 42 Anaplas. Astrocytoma
EMC-29 F 53 Anaplas. Astrocytoma
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Additional file 1: Identification RL-07. Identification of RL-07 by PCR
analyses. PCR analyses were performed on small freeze-thaw-lysate
samples of the viral batches. Samples were heat inactivated and treated
with proteinase K prior to PCR analysis. The i-leader region was amplified
with the following primer set: Fwd primer 5’-
AGACGCTCGGTGCGAGGATGCG; Rev primer 3’-
GTCGTCTTCACGCAGAGGCGC. The PCR product was purified according to
the SureClean protocol (Bioline, London, UK) and the product was
digested using XhoI and loaded on 2% agarose gel. The picture
represents the photo-negative image.
Additional file 2: Alignment i-leader region. Sequencing analyses
were performed on PCR products of freeze-thaw samples of virus
batches (described by identification RL-07). PCR products were first
cleaned with Sureclean (Bioline, London, UK), according to the manual,
before direct sequencing. Sequencing was performed at the Leiden
Genome Technology Center (LGTC, Leiden, The Netherlands). The
sequences of nucleotide 8300-8400 of the parental plasmid pTG3602 and
the sequences of the HAdV-5 and RL-07 viruses are represented. The
C8350T changes, as well as the XhoI site created in the RL-07 virus, are
boxed.
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Figure 6 Relative survival of infected cells as determined by WST-1 assay. Cytopathic activity of RL-07 (grey bar) compared to wtHAdV-5
(black bar) is higher on primary high grade glioma cell cultures. Error bars represent SD (n = 4). * - statistical significance; paired, two sided t-test,
p < 0.01. Cells were seeded in 96-well plates 1 day prior infection with RL-07 and wtHAdV-5 (MOI range 0-100 pfu/cell). Viability of the cultures
was determined by WST-1 assay 7 days p.i..
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